创新的基于设备的高血压治疗方法
Min Zhang1, Peng Li2,3, Yanhui Sheng1,4
1Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
American journal of hypertension
|December 4, 2025
概括
在全球范围内,高血压影响了128亿人,增加了中风和心脏病的风险. 针对自主神经系统的基于设备的疗法为抗性高血压提供了新的治疗途径.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 神经学 神经学
背景情况:
- 从1990年到2019年,全球高血压患病率翻了一番,影响了128亿人.
- 血压升高显著增加了中风,冠状动脉疾病 (CAD),心力衰竭 (HF) 和慢性病 (CKD) 的风险.
- 耐性高血压 (RH) 被定义为尽管服用多种抗高血压药物,但仍无法控制血压,需要使用替代治疗策略.
研究的目的:
- 审查基于设备的抗高血压疗法的病理生理基础.
- 批判性地评估这些干预措施的当前临床证据.
- 突出在临床实践中基于设备的治疗方法的未来方向.
主要方法:
- 对基于设备的抗高血压疗法的现有文献的审查.
- 针对自主神经系统的病理生理机制的分析.
- 评估临床试验数据和结果.
主要成果:
- 基于设备的疗法,包括脏缩和巴罗受体激活,主要针对自主神经系统.
- 对这些干预措施的现有临床证据进行了批判性评估.
- 讨论了未来的研究和临床整合途径.
结论:
- 基于设备的疗法是治疗耐药高血压的一个有希望的前沿.
- 需要进一步的研究来优化技术并确认长期的疗效和安全性.
- 将其整合到临床实践中需要强有力的证据和标准化的协议.
相关概念视频
Hypertension IV: Drug Therapy and Lifestyle Modifications
578
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
578
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
Heart Failure V: Medical Management
200
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
418
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
418


